Chemours downgraded to Neutral from Buy at UBS

UBS analyst Joshua Spector downgraded Chemours to Neutral from Buy with a price target of $21, down from $37. The analyst sees the company’s ongoing investigation and internal changes as an overhang for the stock. With issues ranging from “tone at the top” to accounting issues, it is difficult to gauge the extent of the issue without further information, the analyst tells investors in a research note. UBS says it is difficult to recommend the stock pending more visibility.